30 closest matches · ranked by relevance
Nasolacrimal Duct Obstruction
Primary: Proportion of Participants With Treatment Success — 0.92; 0.82 proportion of participants — p=0.09
Congenital Nasolacrimal Duct Obstruction
Primary: Change in Physician-rated Scale of NLDO From Baseline to Follow-Up Visit at Week 8 or From Baseline to Time of Treatment Failure, if Earlier. — 7; 10; 1; 1 participants
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Stimulated Acute Tear Production — 17.28; 7.92 Scores on a scale
Dry Eye Syndrome · Keratoconjunctivitis Sicca
Primary: Acute Stimulated Tear Production — 25.3; 9.2; 9.5 mm
Dry Eye Syndromes
Primary: Change From Pre-Application to Post-Application in the Ora Calibra Ocular Discomfort Scale (ODS) Score — -1.1; -0.4 score on a scale — p=0.008
Dry Eye · Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Acute Tear Production by Jones Schirmer Test
Dry Eye Syndrome · Keratoconjunctivitis Sicca
Primary: Tear Meniscus Height Captured by Optical Coherence Tomography — 238.4; 634.9 µm
Dry Eye Syndromes
Primary: Investigators' Evaluation of the Tear Lake; Comparison of Baseline Result to 7 Days — 129 mean percent change from baseline
Dry Eye Syndromes
Primary: Fluorescein Tear Clearance With Application
Nasal Obstruction
Primary: Change in Peak Nasal Inspiratory Flow (PNIF) — 28; 24; 13; 27 liters per minute
Dry Eye Disease
Primary: Mean Change in Goblet Cell Area — -38.8; -6.7 um
Nasal Obstruction
Primary: Improvement in NOSE Score — 54.8 units on a scale — p=<0.0001
Dry Eye Syndromes · Sjogren's Syndrome
Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.
Dry Eye Disease
Primary: Mean Change in Schirmer's Test Score From Baseline to 28 Days — 10.1; 11.7; 11.0; 3.2 score on a scale, mm
Nasal Obstruction
Primary: Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline…
Dry Eye Disease
Primary: Mean Change in Schirmer's Test From Baseline to 28 Days — 10.5; 5.7 mm
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 1.68; 2.66 units on a scale
Chronic Allergic Conjunctivitis
Primary: Ocular Itching — 1.80; 2.58; 1.72; 2.70 units on a scale (0 -4)
Dry Eye Syndromes
Primary: Change From Pre-Application to Post-Application in Eye Dryness Score (EDS) Using a Visual Analog Scale (VAS) — -16.48; -3.12 score on a scale — p=<0.0001
Nasal Obstruction
Primary: Change in NOSE Score — -44.5 units on a scale
Dry Eye
Primary: Total Corneal Fluorescein Staining — 4.09; 5.05 units on a scale
Dry Eye Disease (DED)
Primary: Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28) — 123; 121; 70 Participants
Adenoids
Primary: Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score — 3.89; 1.26 Score on a scale
Sinusitis
Primary: Change in SNOT-20 Score — 2.3; 0.7 score on a scale — p=<0.0001
Long Term Follow up Dry Eye Disease
Primary: Number of Participants With the Left Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations — 0; 0; 0; 0 Participants
Chronic Sinusitis · Polyposis
Primary: Olfaction — 20.2; 19.8 units on a scale
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 2.04; 2.31 units on a scale
Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 (7 Days Post-insertion) — 1.80; 2.69 units on a scale
Dry Eye Disease (DED)
Primary: Thickness of the Mucus-aqueous Tear Film Layer — 3920.3 nm
Dry Eye Disease
Primary: Schirmer's Test Score at Day 1 — 9.0; 17.5; 19.6; 3.0 mm